Showing results (41-50 of 109) with videos related to
Sort By:
Pageof 11
Hypertension (Dallas, Tex. : 1979)|June 17, 2009
Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudySimon Thom, Christoph Stettler, Alice Stanton, et al.Journal of Hypertension|June 22, 2022
Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patientsSilvia Oggero, Thomas Godec, Rick van Gorp, et al.European Journal of Preventive Cardiology|July 23, 2021
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER TrialPeter Sever, Ioanna Gouni-Berthold, Anthony Keech, et al.Journal of the American College of Cardiology|July 13, 2010
Wave reflection predicts cardiovascular events in hypertensive individuals independent of blood pressure and other cardiovascular risk factors: an ASCOT (Anglo-Scandinavian Cardiac Outcome Trial) substudyCharlotte Manisty, Jamil Mayet, Robyn J Tapp, et al.BMJ Open|August 9, 2015
Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertensionMorris J Brown, Bryan Williams, Thomas M MacDonald, et al.BMJ Open|August 9, 2015
Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertensionBryan Williams, Thomas M MacDonald, Mark Caulfield, et al.Plos One|April 11, 2022
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumabLaura E Korthauer, Robert P Giugliano, Jianping Guo, et al.European Heart Journal|December 6, 2006
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes TrialPeter Sever, Björn Dahlöf, Neil Poulter, et al.BMJ Open|August 9, 2015
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trialThomas M MacDonald, Bryan Williams, Mark Caulfield, et al.Cardiovascular Research|March 4, 2025
A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunctionMonika Papworth, Spoorthy Kulkarni, Madeleine Antonsson, et al.Pageof 11